Hemostatic Agents for Kidney Stones

This trial tests whether a hemostatic agent (a substance that helps stop bleeding) can reduce bleeding during a kidney stone procedure called percutaneous nephrolithotomy (PCNL). Participants will either receive a hemostatic agent or not, and the study will compare the outcomes. The goal is to determine if these agents help reduce the drop in hemoglobin (a protein in blood that carries oxygen) during and after the procedure. Individuals with a kidney stone larger than 1.2 cm who are scheduled for PCNL might be suitable candidates for this trial. As an unphased trial, this study offers participants the chance to contribute to important research that could improve future kidney stone procedures.

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Previous studies have used treatments like Floseal, Surgicel, and Surgiflo to help stop bleeding during surgeries. Research has shown that these products are generally safe for patients.

One study found no complications, such as bleeding or urine leaks, when Floseal was used correctly in kidney stone procedures, suggesting its safety for these treatments.

Surgicel has been studied and is considered effective in reducing bleeding. Although specific safety data is limited, its common use in surgeries suggests it is usually safe for patients.

Reports indicate that Surgiflo reduces issues like urine leakage in kidney stone surgeries, suggesting it can be a safe option for managing bleeding.

Researchers are excited about these treatments for kidney stones because they explore different hemostatic agents to control bleeding during surgical procedures. Unlike standard practices that typically involve direct pressure or cauterization, these treatments incorporate agents like Floseal, Surgicel, and Surgiflo with balloon tamponade. These agents work by enhancing the body's natural ability to form clots, potentially reducing bleeding more effectively and quickly. This approach could lead to less invasive procedures, reduced recovery time, and better overall outcomes for patients undergoing kidney stone surgery.

This trial will compare the effectiveness of different hemostatic agents used during kidney stone removal surgery. Research has shown that agents like Floseal, Surgicel, and Surgiflo can help control bleeding. Participants in this trial will receive Balloon Tamponade with one of these agents or Balloon Tamponade alone as a control. Specifically, studies have found that Floseal effectively clears stones without causing bleeding problems. Surgicel is known for its safety and efficiency in surgeries, while Surgiflo has demonstrated good results in reducing bleeding. These agents aid blood clotting at the surgery site, potentially reducing blood loss during procedures like percutaneous nephrolithotomy (PCNL). While each agent appears promising, their exact effectiveness in reducing blood loss and improving blood clotting during PCNL is still under investigation in this trial.²⁵⁶⁷⁸